课题基金 / 基金详情

Defining the Molecular Mechanisms and Clinical Implications of p66ShcA as a Driver of the Epithelial to Mesenchymal Transition in Breast Cancer

Defining the Molecular Mechanisms and Clinical Implications of p66ShcA as a Driver of the Epithelial to Mesenchymal Transition in Breast Cancer
定义 p66ShcA 作为乳腺癌上皮间质转化驱动因素的分子机制和临床意义
批准号：
291181
负责人：
Ursini-Siegel Giuseppina
金额：
$49.94万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2013
资助国家：
加拿大
项目状态：
已结题
起止时间：
2013-09-01 至 2018-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=291181&lang=en
关键词：
Basal Subtype Breast Cancer Epithelial To Mesenchymal Transition Luminal Subtype Met Metastasis P66shca Reactive Oxygen Species Signal Transduction Transgenic Mice

项目摘要

项目成果

Ursini-Siegel Giuseppina的其他基金

相似基金

相关文献

中文摘要
翻译
乳腺癌在分子上是不同的，包括至少五种特定的亚型，每种亚型都有独特的临床结果。 在管腔亚型内分层的乳腺肿瘤通常被认为是良好的结果，尽管一部分患有管腔型乳腺癌的妇女，
英文摘要
Breast cancers are molecularly distinct and include at least five specific subtypes each having unique clinical outcomes. Breast tumors that stratify within the luminal subtypes are generally considered as good outcome, although a subset of women with lu
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inducing oxidative stress as a mechanism to increase the clinical impact of complex I inhibitors in treating aggressive breast cancers.
Capitalizing on an oxidative stress response to sensitize poor outcome cancers to PARP inhibitors
Understanding how oxidative stress influences tumor evolution via metabolic reprogramming
Defining the mechanisms and therapeutic potential of ShcA-mediated angiogenesis and metabolism that fuel breast tumorigenesis
海外基金